flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 Patients with type 2 #diabetes and chronic disease are at high risk for kidney failure, cardiovascular events, and death. ⁣ ⁣ Whether treatment with would mitigate these risks is unknown. ⁣ ⁣ Semaglutide and Cardiovascular Outcomes in

Lyophilisation is a complex freeze-drying process that removes water from a biological or chemical sample while preserving its molecular structure

[1] Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, which typically diminish with continued use

Approximately 10-20% of Hashimotos patients have elevated TgAb without elevated TPO antibodies

Pfizer halted development of its oral GLP-1 danuglipron in 2025 after a trial participant developed liver injury, reflecting safety concerns that require ongoing monitoring with real-world data

Liquids bypass this issue

It is important to note that currently only two GLP-1 RA agents have the indication for management of obesity: Wegovy (semaglutide) and Saxenda (liraglutide)